FDA Approves Lipfendra, the First Oral PCSK9 Pill

Merck's new cholesterol pill Lipfendra got its FDA green light on July 16, 2026. It's the first oral PCSK9 inhibitor ever approved, a class of cholesterol drug that until now only existed as an injection. If you've been on Repatha or Praluent and dreaded the needle, this is the news you've been waiting for.

What Lipfendra Actually Does

The generic name is enlicitide, and chemically it's what's called a macrocyclic peptide, basically a ring-shaped molecule engineered to block a protein called PCSK9. That protein normally works against you: it breaks down the liver receptors that pull LDL cholesterol out of your bloodstream. Block PCSK9, and your liver keeps more of those receptors around, so it clears out more LDL.

You take it as one 20 mg tablet each morning, on an empty stomach, with water, black coffee, or plain tea. That timing detail matters more than it sounds like it should. Absorption of peptide drugs like this one is notoriously picky about what's in your stomach.

The Trial Numbers, Plainly

Two Phase 3 trials backed this approval, run together as the CORALreef program. Between them, more than 3,200 adults were enrolled, all already on the highest statin dose they could tolerate, meaning this wasn't tested on people who hadn't tried anything else first.

In the broader trial, CORALreef Lipids, Lipfendra cut LDL cholesterol by 56% compared with placebo after 24 weeks. In CORALreef HeFH, which focused on people with heterozygous familial hypercholesterolemia, an inherited condition that causes very high cholesterol from a young age, the reduction was 59%. It also lowered other markers doctors track for heart risk, including ApoB and non-HDL cholesterol.

Those numbers are genuinely in the same range as the injectable PCSK9 drugs already on the market. That's the headline, and it's a fair one.

[REVIEWER: this is a good spot for a line grounded in real clinical practice, for example how often patients you've treated struggle with injection adherence versus a daily pill, or what you actually tell patients about the empty-stomach dosing requirement]

What It Doesn't Tell Us Yet

Here's the part that gets buried in a lot of the coverage: none of this proves Lipfendra prevents heart attacks or strokes. The trials measured LDL reduction, not cardiovascular outcomes. The FDA accepts LDL lowering as a validated stand-in for lower cardiovascular risk, and that's a reasonable regulatory shortcut, but it's still a shortcut.

A larger outcomes trial, CORALreef Outcomes, has already finished enrolling more than 14,500 people and is underway to answer that exact question. Until those results come in, doctors are extrapolating from decades of LDL-lowering data with other drugs, not from Lipfendra-specific outcomes.

Merck received approval through the FDA's Commissioner's National Priority Voucher program, which compresses review timelines from the usual 6 to 12 months down to 1 to 2 months for drugs tied to national health priorities. Faster review isn't the same as a shortcut on safety data, but it's worth knowing the approval moved unusually quickly.

Who Might Actually Be a Candidate

Lipfendra is approved as an add-on to diet and exercise for adults with hypercholesterolemia, including those with HeFH, who need more LDL lowering than they're getting from current treatment. Realistically, that means people already on a statin, ideally maxed out, who still aren't hitting their target numbers.

It's not a first-line replacement for statins, and nothing about this approval changes that. If your LDL is well controlled on a statin alone, this isn't a drug your doctor is likely to add just because a pill sounds easier than a shot.

A cholesterol number rarely shows up alone, either. It's usually part of a wider picture that includes blood pressure, blood sugar, weight, and family history, so managing it well often means coordinating across a couple of specialists rather than a single prescription.

Related care on Doctar

Find a cardiologist near you to discuss whether an add-on LDL-lowering drug fits your treatment plan
Consult a general physician if you're not yet sure whether you need a specialist referral
Talk to a dietitian about diet-based LDL reduction alongside any medication
See an endocrinologist if your high cholesterol overlaps with diabetes or thyroid issues, which is common
Book diagnostic lab testing for a lipid panel to check LDL, HDL, and triglycerides before starting treatment
Find diagnostic centers near you for regular cholesterol monitoring
Search hospitals near you if your cardiologist recommends further cardiac workup
Read about angioplasty if uncontrolled LDL has already led to arterial blockage
Read about bypass surgery for context on advanced cardiovascular intervention
Order medicines for delivery if you're managing cholesterol alongside diabetes care
Book a home-visit doctor if regular clinic visits for monitoring are difficult
Check emergency services near you for chest pain or suspected cardiac events, which need immediate care, not a blog post
Learn more about Doctar and how the platform connects patients with verified doctors